Swiss pharmaceutical company Novartis announced on Thursday its plan to separate its generics and biosimilars division, Sandoz into a new publicly traded standalone company. It will be done via a 100% spin-off with an aim to maximise shareholder value by creating a European generics company. Sandoz would be headquartered in Switzerland and listed on the SIX Swiss Exchange.